HLX3901
/ Fosun Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 19, 2026
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC
(clinicaltrials.gov)
- P1 | N=138 | Not yet recruiting | Sponsor: Shanghai Henlius Biotech
First-in-human • New P1 trial • Endocrine Cancer • Lung Cancer • Neuroendocrine Carcinoma • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3
1 to 1
Of
1
Go to page
1